A multi-stakeholder consensus roadmap published in the British Journal of Cancer outlines how clinical trials for rare childhood central nervous system tumors could be redesigned to move faster and broaden inclusion. The report targets structural bottlenecks—especially the gap between scientific discovery and trial infrastructure in understudied pediatric neuro-oncology. The roadmap aims to make trial systems more practical for rare diseases, emphasizing approaches that can support enrollment and standardization across limited patient populations. The effort reflects ongoing pressure to modernize evidence generation in pediatric oncology where cohort sizes are small. For biotech planning trials in pediatric neuro-oncology, the document provides actionable guidance on process and trial conduct—areas that increasingly determine whether assets can generate registrational-quality data.